Dynamic T-Cell Reprogramming Modulates the Treatment Outcome of Neoadjuvant Immunochemotherapy in Non-Small-Cell Lung Cancer - PubMed
19 hours ago
- #NSCLC
- #T-cell dynamics
- #Immunochemotherapy
- Dynamic T-cell reprogramming influences the outcome of neoadjuvant immunochemotherapy in non-small-cell lung cancer (NSCLC).
- Two-thirds of patients respond poorly to perioperative chemoimmunotherapy, highlighting the need to understand underlying mechanisms.
- Using single-cell RNA and T-cell receptor sequencing on paired pre- and post-treatment samples, bidirectional T-cell mechanisms linked to pathological response were identified.
- Responders showed higher TCR clonality and diversity in CD8+ T-cell subsets, including effector memory, effector, tissue-resident memory, and exhausted T cells.
- CD8+ effector memory T cells, with both novel and pre-existing TCR clonal expansion, were particularly associated with improved pathological responses.
- In nonresponsive tumors, inhibitory Tregs exhibited more novel clonal expansion and enhanced functional profiles, contributing to poor outcomes.